Kepos Capital’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Kepos Capital’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-230,022	Closed	-$151K	–	73
2024 Q4	$151K	Buy	+230,022	New	+$93.8K	0.13%	33
2022 Q3	–	Sell	-525,000	Closed	-$5.1M	–	508
2022 Q2	$5.1M	Hold	525,000	–	–	0.47%	71
2022 Q1	$5.09M	Hold	525,000	–	–	0.38%	111
2021 Q4	$5.08M	Buy	+525,000	New	+$5.11M	0.42%	97

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Kepos Capital's NKGN Position: Q1 2025 in Review

Kepos Capital sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 230,022 shares — an estimated $151K sold.

Kepos Capital first reported a position in NKGN in Q4 2021 and held it in 4 quarters. The position peaked at $5.1M in Q2 2022. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

Kepos Capital reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Kepos Capital sold 230,022 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $151K.
Kepos Capital first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Kepos Capital's NKGen Biotech, Inc. Common Stock position peaked at $5.1M in Q2 2022.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Kepos Capital's 13F filing for Q1 2025, filed 13 May 2025.